ITVISMA 40000000000000 [arb'U]/mL
onasemnogene abeparvovec-brve · INJECTION, SUSPENSION · Novartis Gene Therapies, Inc.
Itvisma is a gene therapy injection administered directly into the spinal fluid to treat spinal muscular atrophy (SMA), a rare genetic disorder that affects nerve cells controlling muscle movement. It is a one-time treatment designed to provide a functional copy of the missing or defective gene responsible for SMA.
Key Facts
- Brand Name
- ITVISMA
- Generic Name
- onasemnogene abeparvovec-brve
- NDC Code (Product)
71894-200- Manufacturer
- Novartis Gene Therapies, Inc.
- Strength
- 40000000000000 [arb'U]/mL
- Dosage Form
- INJECTION, SUSPENSION
- Route
- INTRATHECAL
- Marketing Status
- Application #
- BLA125856
- Marketing Start
- 11/24/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is ITVISMA used for?
Itvisma is a gene therapy injection administered directly into the spinal fluid to treat spinal muscular atrophy (SMA), a rare genetic disorder that affects nerve cells controlling muscle movement. It is a one-time treatment designed to provide a functional copy of the missing or defective gene responsible for SMA.
Is ITVISMA a controlled substance?
ITVISMA is not classified as a controlled substance by the DEA.
What is the generic name for ITVISMA?
The generic name for ITVISMA is onasemnogene abeparvovec-brve. There are no other listed brand versions of onasemnogene abeparvovec-brve.
What is the NDC code for ITVISMA 40000000000000 [arb'U]/mL?
The NDC (National Drug Code) for ITVISMA 40000000000000 [arb'U]/mL is 71894-200, listed by Novartis Gene Therapies, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)